In the Pipeline

This is our second generation of Brucella vaccine for catlle. The first one was created by combination of two recombinant viruses and shown to be effective (more information).

Current development is based on one recombinant virus with a number of modifications we have developed recently.

Building on our UniFluVec virus vector, which already provides effective CTL protection against H1N1 and H3N2 viruses, we are creating a vaccine enriched with regions containing conserved immunodominant CTL epitopes for various swine haplotypes.

The objective is to create a novel protective circovirus vaccine that is equally effective against all PCV2 subtypes and variants worldwide, providing protection across most swine breeds and haplotypes.

The vaccine is currently undergoing detailed immunological studies and challenge tests.

 The project aims to develop a cross-protective CTL vaccine effective against A-type viruses specific to the target animals. This will be accomplished by incorporating CTL epitopes that exhibit stability across different serotypes of the flu virus observed in horses and camels.

Existing anti-PRSSV vaccines, primarily aimed at inducing humoral responses, struggle to keep pace with the virus's spread in infected animals. This project aims to develop a vaccine that triggers an effective protective CTL response against multiple variants of PRRS virus.

 The cattle vaccine against tuberculosis has been developed, and currently undergoes immunological tests prior to the challenge test and field tests in cattle farms..